Dublin, Sept. 25, 2017 -- The "Global Multiple Sclerosis Market: Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)" report has been added to Research and Markets' offering.
Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022
Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market.
Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country.
Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price.
Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground
Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.
Key Topics Covered:
1. Research Findings
2. Global Multiple Sclerosis Patient Numbers (2011 - 2022)
3. Global Multiple Sclerosis Market (2011 - 2022)
4. Patient Share - Global Multiple Sclerosis (2011 - 2022)
5. Market Share - Global Multiple Sclerosis (2011 - 2022)
6. United Kingdom
7. France
8. Germany
9. Italy
10. Spain
11. United States
12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents)
13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
For more information about this report visit https://www.researchandmarkets.com/research/56wqtx/global_multiple
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Central Nervous System Drugs , Infusions and Injectables


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



